OncLive® On Air S14 Ep62: VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD
Dec 5, 2025
Dr. Catherine Shu, a leading expert in thoracic oncology at Columbia University, discusses the promising results of tepotinib in treating non-small cell lung cancer with MET exon 14 skipping mutations. She delves into the phase 2 VISION trial, highlighting impressive efficacy, early response rates, and long-term follow-up data. Dr. Shu emphasizes the need for next-generation sequencing in early detection and shares insights on managing side effects, ensuring patient safety throughout treatment. It's a deep dive into targeted therapies that could reshape cancer care.
AI Snips
Chapters
Transcript
Episode notes
VISION Is The Largest METex14 Trial
- The VISION trial is the largest study of metastatic NSCLC with MET exon 14 skipping mutations and included both treatment‑naive and previously treated patients.
- It used objective response rate as the primary endpoint and allowed enrollment by liquid and tissue biopsy.
Durable Responses Seen In Longer Follow‑Up
- Initial VISION results showed rapid and substantial responses with investigator‑assessed ORR up to 56% and median DOR ~11 months.
- Long‑term follow‑up across two cohorts (313 patients) showed ORRs ~51%–56% and median DOR up to ~21 months, with treatment‑naive patients faring best.
Big Benefit For Treatment‑Naive Patients
- The updated JAMA Oncology data highlighted markedly better outcomes in treatment‑naive patients, including a median DOR of ~46 months.
- Over 40% of patients experienced responses lasting more than one year, emphasizing first‑line benefit.